Latest ebit for RAFA: $540K, below the sector sector average of $2.4T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Rafarma Pharmaceuticals (RAFA) currently reports a EBIT of $540K as of September 2026. That compares with $400K in the prior-year period — up 34.4% year over year. That is below the sector sector average of $2.4T. Use the charts on this page to explore Rafarma Pharmaceuticals's EBIT history and peer comparisons.
Rafarma Pharmaceuticals's EBIT increased from $400K to $540K — a 34.4% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Rafarma Pharmaceuticals's EBIT of $540K is lower than the its sector sector average of $2.4T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Rafarma Pharmaceuticals reported $540K in EBIT as of September 2026. That compares with $400K in the prior-year period — up 34.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $540K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.4T. From there, open related valuation or income-statement pages for Rafarma Pharmaceuticals, and consider following RAFA for alerts when major investors trade the stock.